Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

ST. JOSEPH HEALTH SERVICES OF RI

NPI: 1992840862 · NORTH PROVIDENCE, RI 02904 · Anatomic Pathology & Clinical Pathology Physician · NPI assigned 02/20/2007

Deactivated NPI · This NPI was deactivated on 09/19/2007. Reactivated 12/22/2009.
$5.84M
Total Medicaid Paid
74,516
Total Claims
63,895
Beneficiaries
115
Codes Billed
2018-01
First Month
2020-01
Last Month

Provider Details

Authorized OfficialFOGARTY, JOHN (PRESIDENT)
Parent OrganizationST JOSEPH HEALTH SERVICES OF RI
NPI Enumeration Date02/20/2007

Related Entities

Other providers sharing the same authorized official: FOGARTY, JOHN

ProviderCityStateTotal Paid
IRVINE UNIFIED SCHOOL DISTRICT IRVINE CA $4.94M
BREA-OLINDA SCHOOL DISTRICT BREA CA $702K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 32,007 $2.77M
2019 42,471 $3.06M
2020 38 $21K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
41899 Unlisted procedure, dentoalveolar structures 595 326 $1.41M
99283 Emergency department visit for the evaluation and management, moderate severity 2,325 1,924 $1.22M
99284 Emergency department visit for the evaluation and management, high severity 1,605 1,205 $836K
99285 Emergency department visit for the evaluation and management, high severity with immediate threat to life 728 536 $375K
99282 Emergency department visit for the evaluation and management, low to moderate severity 426 378 $222K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 2,752 2,437 $174K
80061 Lipid panel 3,989 3,530 $114K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 1,506 1,324 $113K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 1,505 1,324 $112K
80050 General health panel 2,222 1,971 $108K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 932 762 $98K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 1,139 938 $76K
84443 Thyroid stimulating hormone (TSH) 1,783 1,592 $64K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 3,217 2,760 $58K
80053 Comprehensive metabolic panel 1,948 1,728 $45K
83036 Hemoglobin; glycosylated (A1C) 2,109 1,878 $39K
82607 1,112 967 $36K
80048 Basic metabolic panel (calcium, ionized) 1,862 1,600 $35K
80074 338 293 $34K
87070 414 354 $27K
87480 586 517 $25K
87510 585 516 $25K
87086 Culture, bacterial; quantitative colony count, urine 2,138 1,821 $24K
82728 699 604 $20K
84439 1,052 933 $20K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 197 66 $19K
81001 2,814 2,442 $19K
84154 483 411 $19K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine 520 497 $18K
86803 615 542 $18K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 1,140 1,027 $17K
87186 767 656 $16K
85027 1,126 992 $16K
36415 Collection of venous blood by venipuncture 10,445 8,721 $16K
88142 362 312 $15K
80076 851 735 $15K
86706 661 598 $15K
86618 409 343 $15K
84466 522 455 $14K
90791 Psychiatric diagnostic evaluation 136 121 $14K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 260 211 $13K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 79 59 $11K
99394 Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) 176 146 $11K
87081 745 648 $11K
96127 442 402 $10K
82746 454 386 $10K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 55 53 $10K
87340 468 421 $10K
86141 358 298 $10K
83540 715 623 $10K
86038 380 330 $10K
82043 672 600 $8K
84460 674 594 $8K
87660 585 516 $7K
82550 497 436 $7K
84450 609 538 $7K
86592 712 642 $6K
99393 Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) 106 95 $6K
85652 1,033 884 $6K
82565 526 465 $6K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 78 59 $6K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 253 217 $6K
87077 363 305 $6K
90472 Immunization administration, each additional vaccine (list separately) 174 161 $5K
84403 87 83 $5K
83690 314 263 $5K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 116 101 $5K
82150 317 270 $4K
87205 382 331 $4K
86431 287 248 $3K
86696 82 80 $3K
80051 232 214 $3K
85610 371 242 $3K
82947 355 314 $3K
88305 Level IV - Surgical pathology, gross and microscopic examination 16 16 $3K
84436 185 161 $3K
84520 318 281 $3K
83735 184 156 $3K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 25 22 $2K
86695 82 80 $2K
84550 243 213 $2K
86665 62 24 $2K
86694 70 69 $2K
84153 50 42 $2K
77067 Screening mammography, bilateral, including computer-aided detection 40 38 $2K
83013 13 13 $2K
84480 59 46 $2K
82962 266 206 $2K
86704 64 55 $2K
86617 48 12 $2K
86762 41 41 $1K
84270 28 28 $1K
83721 87 81 $1K
86787 41 40 $1K
86765 40 40 $1K
84481 87 78 $1K
86664 31 24 $993.86
82040 117 100 $858.80
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 16 12 $852.32
86663 31 24 $852.19
80358 81 60 $847.08
86735 27 27 $791.37
80353 77 53 $727.33
99392 Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) 12 12 $673.80
77063 Screening digital breast tomosynthesis, bilateral 40 38 $483.80
86677 13 12 $395.33
84702 12 12 $378.48
86225 12 12 $345.48
83655 32 27 $334.26
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 13 12 $285.48
84484 17 12 $248.78
90785 38 36 $243.97
86200 26 13 $208.65
85730 13 12 $163.67
90686 287 284 $55.83